Search

Your search keyword '"Yanaihara, Nozomu"' showing total 293 results
Start Over Author "Yanaihara, Nozomu"
293 results on '"Yanaihara, Nozomu"'

3. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis

Author

Corbaux, Pauline, You, Benoit, Glasspool, Rosalind M., Yanaihara, Nozomu, Tinker, Anna V., Lindemann, Kristina, Ray-Coquard, Isabelle L., Mirza, Mansoor R., Subtil, Fabien, Colomban, Olivier, Péron, Julien, Karamouza, Eleni, McNeish, Iain, Kelly, Caroline, Kagimura, Tatsuo, Welch, Stephen, Lewsley, Liz-Anne, Paoletti, Xavier, and Cook, Adrian

Published
2023
Full Text
View/download PDF

4. Personalized Treatment in Ovarian Cancer

Author

Yanaihara, Nozomu, Iida, Yasushi, Takenaka, Masataka, Kawabata, Ayako, Kuroda, Takafumi, Okamoto, Aikou, Konishi, Ikuo, Series Editor, Katabuchi, Hidetaka, Series Editor, and Mandai, Masaki, editor

Published
2022
Full Text
View/download PDF

6. Y-box binding protein 1/cyclin A1 axis specifically promotes cell cycle progression at G2/M phase in ovarian cancer.

Author

Murakami, Yuichi, Katsuchi, Daisuke, Matsumoto, Taichi, Kanazawa, Kuon, Shibata, Tomohiro, Kawahara, Akihiko, Akiba, Jun, Yanaihara, Nozomu, Okamoto, Aikou, Itamochi, Hiroaki, Sugiyama, Toru, Terada, Atsumu, Nishio, Shin, Tsuda, Naotake, Kato, Kiyoko, Ono, Mayumi, and Kuwano, Michihiko

Abstract

Y-box binding protein 1 (YBX1) promotes oncogenic transformation and tumor growth. YBX1 plays a role in regulation of cell cycle promotion via upregulation of cell cycle-related genes. In ovarian cancer, YBX1 also promotes tumor growth, but the mechanisms of YBX1 in cell growth and cell cycle in ovarian cancer remain not to be fully understood. Here, we investigated whether YBX1-dependent cancer cell proliferation was specifically associated with expression of cell cycle related genes in ovarian cancer. Protein and mRNA expression levels of YBX1 and cell cycle-related genes in ovarian cancer cell lines and tissues were determined by western blot analysis, immunohistochemical analysis and reverse transcription-quantitative PCR. Cell cycle analysis was performed by flow cytometry. Luciferase assay and Chromatin immunoprecipitation assay were used to investigate a transcriptional function of YBX1. YBX1 silencing induced marked growth suppression in 4 cell lines (group A), moderate suppression in 5 cell lines (group B), and no suppression in 3 cell lines (group C) among 12 ovarian cancer cell lines in culture. The YBX1 silencing induced cell cycle arrest at G2/M phase and suppressed expression of cyclin A1 gene in group A and B cell lines, but not in group C cell lines. Cyclin A1 silencing specifically suppressed cell proliferation in group A cell lines and partially in group B cell lines, but not at all in group C cell lines. YBX1 mRNA levels were significantly correlated with cyclin A1 mRNA levels in patients with high-grade serous carcinoma. Augmented YBX1 expression plays a key role in tumor growth promotion in ovarian cancer in its close association with cyclin A1. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. EP169/#411 Machine learning method for differential diagnosis and prognosis prediction for early-stage uterine sarcoma using preoperative blood biomarker and age

Author

Shoburu, Yuichi, primary, Yanaihara, Nozomu, additional, Tabata, Junya, additional, Nishimura, Ryoga, additional, Shimazaki, Miwako, additional, Oka, Kazuhiko, additional, Kubonoya, Yutaro, additional, Kobayashi-Ogasawara, Ritsuko, additional, Honda, Rie, additional, Yamada, Atsuko, additional, Saito, Motoaki, additional, Yamada, Kyosuke, additional, Takano, Hirokuni, additional, Terao, Yasuhisa, additional, Kawakami, Eiryo, additional, and Okamoto, Aikou, additional

Published
2023
Full Text
View/download PDF

13. EP260/#470 Effect of dose-dense paclitaxel plus carboplatin with or without bevacizumab for Japanese epithelial ovarian cancer: a single-center retrospective study

Author

Kochi, Yuki, primary, Hosoya, Satoshi, additional, Odajima, Suguru, additional, Kuroda, Takafumi, additional, Takahashi, Kazuaki, additional, Nagata, Chie, additional, Saito, Motoaki, additional, Yanaihara, Nozomu, additional, Tanabe, Hiroshi, additional, Yamada, Kyosuke, additional, Takano, Hirokuni, additional, and Okamoto, Aikou, additional

Published
2023
Full Text
View/download PDF

21. Supplemental Table S3. from Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers

Author

Kawakami, Eiryo, primary, Tabata, Junya, primary, Yanaihara, Nozomu, primary, Ishikawa, Tetsuo, primary, Koseki, Keita, primary, Iida, Yasushi, primary, Saito, Misato, primary, Komazaki, Hiromi, primary, Shapiro, Jason S., primary, Goto, Chihiro, primary, Akiyama, Yuka, primary, Saito, Ryosuke, primary, Saito, Motoaki, primary, Takano, Hirokuni, primary, Yamada, Kyosuke, primary, and Okamoto, Aikou, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Data from Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype

Author

Takenaka, Masataka, primary, Köbel, Martin, primary, Garsed, Dale W., primary, Fereday, Sian, primary, Pandey, Ahwan, primary, Etemadmoghadam, Dariush, primary, Hendley, Joy, primary, Kawabata, Ayako, primary, Noguchi, Daito, primary, Yanaihara, Nozomu, primary, Takahashi, Hiroyuki, primary, Kiyokawa, Takako, primary, Ikegami, Masahiro, primary, Takano, Hirokuni, primary, Isonishi, Seiji, primary, Ochiai, Kazuhiko, primary, Traficante, Nadia, primary, Gadipally, Sreeja, primary, Semple, Timothy, primary, Vassiliadis, Dane, primary, Amarasinghe, Kausyalya, primary, Li, Jason, primary, Mir Arnau, Gisela, primary, Okamoto, Aikou, primary, Friedlander, Michael, primary, and Bowtell, David D. L., primary

Published
2023
Full Text
View/download PDF

23. Supplemental Figure S1. from Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers

Author

Kawakami, Eiryo, primary, Tabata, Junya, primary, Yanaihara, Nozomu, primary, Ishikawa, Tetsuo, primary, Koseki, Keita, primary, Iida, Yasushi, primary, Saito, Misato, primary, Komazaki, Hiromi, primary, Shapiro, Jason S., primary, Goto, Chihiro, primary, Akiyama, Yuka, primary, Saito, Ryosuke, primary, Saito, Motoaki, primary, Takano, Hirokuni, primary, Yamada, Kyosuke, primary, and Okamoto, Aikou, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Data from MicroRNA Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus: Associations with Survival

Author

Mathé, Ewy A., primary, Nguyen, Giang Huong, primary, Bowman, Elise D., primary, Zhao, Yiqiang, primary, Budhu, Anuradha, primary, Schetter, Aaron J., primary, Braun, Rosemary, primary, Reimers, Mark, primary, Kumamoto, Kensuke, primary, Hughes, Duncan, primary, Altorki, Nasser K., primary, Casson, Alan G., primary, Liu, Chang-Gong, primary, Wang, Xin Wei, primary, Yanaihara, Nozomu, primary, Hagiwara, Nobutoshi, primary, Dannenberg, Andrew J., primary, Miyashita, Masao, primary, Croce, Carlo M., primary, and Harris, Curtis C., primary

Published
2023
Full Text
View/download PDF

29. CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data

Author

Karamouza, Eleni, primary, Glasspool, Rosalind M., additional, Kelly, Caroline, additional, Lewsley, Liz-Anne, additional, Carty, Karen, additional, Kristensen, Gunnar B., additional, Ethier, Josee-Lyne, additional, Kagimura, Tatsuo, additional, Yanaihara, Nozomu, additional, Cecere, Sabrina Chiara, additional, You, Benoit, additional, Boere, Ingrid A., additional, Pujade-Lauraine, Eric, additional, Ray-Coquard, Isabelle, additional, Proust-Lima, Cécile, additional, and Paoletti, Xavier, additional

Published
2023
Full Text
View/download PDF

30. CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data

Author

Karamouza, Eleni, Glasspool, Rosalind M., Kelly, Caroline, Lewsley, Liz Anne, Carty, Karen, Kristensen, Gunnar B., Ethier, Josee Lyne, Kagimura, Tatsuo, Yanaihara, Nozomu, Cecere, Sabrina Chiara, You, Benoit, Boere, Ingrid A., Pujade-Lauraine, Eric, Ray-Coquard, Isabelle, Proust-Lima, Cécile, Paoletti, Xavier, Karamouza, Eleni, Glasspool, Rosalind M., Kelly, Caroline, Lewsley, Liz Anne, Carty, Karen, Kristensen, Gunnar B., Ethier, Josee Lyne, Kagimura, Tatsuo, Yanaihara, Nozomu, Cecere, Sabrina Chiara, You, Benoit, Boere, Ingrid A., Pujade-Lauraine, Eric, Ray-Coquard, Isabelle, Proust-Lima, Cécile, and Paoletti, Xavier

Abstract

(1) Background: Cancer antigen 125 (CA-125) is a protein produced by ovarian cancer cells that is used for patients’ monitoring. However, the best ways to analyze its decline and prognostic role are poorly quantified. (2) Methods: We leveraged individual patient data from the Gynecologic Cancer Intergroup (GCIG) meta-analysis (N = 5573) to compare different approaches summarizing the early trajectory of CA-125 before the prediction time (called the landmark time) at 3 or 6 months after treatment initiation in order to predict overall survival. These summaries included observed and estimated measures obtained by a linear mixed model (LMM). Their performances were evaluated by 10-fold cross-validation with the Brier score and the area under the ROC (AUC). (3) Results: The estimated value and the last observed value at 3 months were the best measures used to predict overall survival, with an AUC of 0.75 CI 95% [0.70; 0.80] at 24 and 36 months and 0.74 [0.69; 0.80] and 0.75 [0.69; 0.80] at 48 months, respectively, considering that CA-125 over 6 months did not improve the AUC, with 0.74 [0.68; 0.78] at 24 months and 0.71 [0.65; 0.76] at 36 and 48 months. (4) Conclusions: A 3-month surveillance provided reliable individual information on overall survival until 48 months for patients receiving first-line chemotherapy.

Published
2023

31. Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway

Author

Yanaihara, Nozomu, primary, Yoshino, Yuki, additional, Noguchi, Daito, additional, Tabata, Junya, additional, Takenaka, Masataka, additional, Iida, Yasushi, additional, Saito, Misato, additional, Yanagida, Satoshi, additional, Iwamoto, Masami, additional, Kiyokawa, Takako, additional, Chiba, Natsuko, additional, and Okamoto, Aikou, additional

Published
2023
Full Text
View/download PDF

33. Knowledge and practice for cervical cancer among female primary school teachers in Phnom Penh, Cambodia: A cross-sectional phone-based survey

Author

Soeung, Sann Chan, primary, Komagata, Tomoko, additional, Darapheack, Chau, additional, Kikuchi, Shikino, additional, Obara, Hiromi, additional, Haruyama, Rei, additional, Kanal, Koum, additional, Fujita, Noriko, additional, Yanaihara, Nozomu, additional, Okamoto, Aiko, additional, and Kimura, Tadashi, additional

Published
2022
Full Text
View/download PDF

35. Prevention and practice during the <scp>COVID</scp> ‐19 emergency declaration period in Japanese obstetrical/gynecological facilities

Author

Komatsu, Hiroaki, Banno, Kouji, Yanaihara, Nozomu, and Kimura, Tadashi

Subjects
Face shield, Infertility, medicine.medical_specialty, business.product_category, Pneumonia, Viral, Asymptomatic, Betacoronavirus, 03 medical and health sciences, COVID-19 Testing, 0302 clinical medicine, Japan, Obstetrics and gynaecology, Pregnancy, Obstetrics and Gynaecology, Pandemic, medicine, Humans, Practice Patterns, Physicians', Pregnancy Complications, Infectious, Pandemics, 030219 obstetrics & reproductive medicine, Clinical Laboratory Techniques, SARS-CoV-2, business.industry, COVID-19, Obstetrics and Gynecology, Questionnaire, Delivery mode, medicine.disease, Obstetrics, Gynecology, 030220 oncology & carcinogenesis, Family medicine, Female, Health Facilities, medicine.symptom, Coronavirus Infections, business
Abstract

Aim A nationwide questionnaire survey was performed to evaluate how Japanese Society of Obstetrics and Gynecology (JSOG) members dealt with the coronavirus disease (COVID-19) pandemic during the declared nationwide emergency. Methods We sent questionnaires to members of JSOG via official email. Participants answered anonymously using Google forms. Results Two (0.08%) JSOG members had contracted COVID-19. There was a clear decrease in the number of patients scheduled for operation, not only for malignant but also for benign diseases. A decrease in the number of outpatients for infertility treatment was also observed. Polymerase chain reaction testing for severe acute respiratory syndrome coronavirus 2 was available in 20.4% of the facilities. Inpatients and outpatients were requested to wear masks, limit the number of contacts and check body temperature when visiting hospitals/clinics. During parturition care, caregivers and physicians wore gloves, masks (other than N-95), face shields and gowns. About 66% and 80% of the facilities decided to transfer pregnant women if they had asymptomatic and symptomatic infection, respectively. Cesarean section was typically chosen as delivery mode in infected women. Conclusion The COVID-19 pandemic provoked significant changes in obstetrics and gynecology practices in Japan. Apparently, nosocomial infections were largely prevented due to these changes, although some of them might not have been necessary.

Published
2020

36. Survival Prognostic and Surrogate Values of the Early Modeled Ca-125 Kelim Score in First-Line Treatment of Ovarian Cancer: Results from The Gcig Individual Patient Data Meta-Analysis

Author

Corbaux, Pauline, primary, You, Benoit, additional, Glasspool, Rosalind M., additional, Yanaihara, Nozomu, additional, Tinker, Anna V., additional, Lindemann, Kristina, additional, Ray-Coquard, Isabelle-Laure, additional, Mirza, Mansoor Raza, additional, Subtil, Fabien, additional, Colomban, Olivier, additional, Péron, Julien, additional, Karamouza, Eleni, additional, McNeish, Iain, additional, Hinsley, Samantha, additional, Kagimura, Tatsuo, additional, Welch, Stephen, additional, Lewsley, Liz-Anne, additional, Paoletti, Xavier, additional, and Cook, Adrian, additional

Published
2022
Full Text
View/download PDF

38. Scoring Systems of Peritoneal Dissemination for the Prediction of Operative Completeness in Advanced Ovarian Cancer

Author

HOSOYA, SATOSHI, primary, UEDA, KAZU, additional, ODAJIMA, SUGURU, additional, OGAWA, KOHEI, additional, KOMAZAKI, HIROMI, additional, SEKI, TOSHIYUKI, additional, TAKENAKA, MASATAKA, additional, SAITO, MOTOAKI, additional, TANABE, HIROSHI, additional, YAMADA, KYOSUKE, additional, TAKANO, HIROKUNI, additional, IIDA, YASUSHI, additional, YANAIHARA, NOZOMU, additional, and OKAMOTO, AIKOU, additional

Published
2021
Full Text
View/download PDF

41. A report on the 73th Annual Congress of the Japan Society of Obstetrics and Gynecology International Workshop for Junior Fellows: Risk‐reducing surgery for hereditary breast and ovarian cancer

Author

Hirayama, Takashi, primary, Inayama, Yoshihide, additional, Odajima, Suguru, additional, Yamanaka, Akina, additional, Sekine, Masayuki, additional, Terao, Yasuhisa, additional, Koide, Keiko, additional, Kuwabara, Yoshimitsu, additional, Yahata, Hideaki, additional, Yanaihara, Nozomu, additional, Nagase, Satoru, additional, Kobayashi, Yoichi, additional, and Sekizawa, Akihiko, additional

Published
2021
Full Text
View/download PDF

44. MicroRNA expression profiles associated with prognosis and therapeutic outcomes in colon adenocarcinoma

Author

Schetter, Aaron J., Leung, Suet Yi, Sohn, Jane J., Zanetti, Krista A., Bowman, Elise D., Yanaihara, Nozomu, Siu Tsan Yuen, Tsun Leung Chan, Kwong, Dora L.W., Au, Gordon K.H., Chang-Gong Liu, Calin, George A., Croce, Carlo M., and Harris, Curtis C.

Subjects
Gene expression -- Research, Colon cancer -- Genetic aspects, Colon cancer -- Research, Colon cancer -- Prognosis, RNA -- Research
Abstract

The study was conducted to identify microRna expression patterns that were associated with colon cancer. Results revealed that the prognosis for patients afflicted with colon cancer was poor.

Published
2008

45. Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer

Author

Paoletti, Xavier, Lewsley, Liz-Anne, Daniele, Gennaro, Cook, Adrian, Yanaihara, Nozomu, Tinker, Anna, Kristensen, Gunnar, Ottevanger, Petronella B., Aravantinos, Gerasimos, Miller, Austin, Boere, Ingrid A., Fruscio, Robert, Reyners, Anna K. L., Pujade-Lauraine, Eric, Harkin, Andrea, Pignata, Sandro, Kagimura, Tatsuo, Welch, Stephen, Paul, James, Karamouza, Eleni, and Glasspool, Rosalind M.

Abstract

Importance: The Gynecologic Cancer InterGroup (GCIG) recommended that progression-free survival (PFS) can serve as a primary end point instead of overall survival (OS) in advanced ovarian cancer. Evidence is lacking for the validity of PFS as a surrogate marker of OS in the modern era of different treatment types.\ud \ud Objective: To evaluate whether PFS is a surrogate end point for OS in patients with advanced ovarian cancer.\ud \ud Data Sources: In September 2016, a comprehensive search of publications in MEDLINE was conducted for randomized clinical trials of systematic treatment in patients with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer. The GCIG groups were also queried for potentially completed but unpublished trials.\ud \ud Study Selection: Studies with a minimum sample size of 60 patients published since 2001 with PFS and OS rates available were eligible. Investigational treatments considered included initial, maintenance, and intensification therapy consisting of agents delivered at a higher dose and/or frequency compared with that in the control arm.\ud \ud Data Extraction and Synthesis: Using the meta-analytic approach on randomized clinical trials published from January 1, 2001, through September 25, 2016, correlations between PFS and OS at the individual level were estimated using the Kendall τ model; between-treatment effects on PFS and OS at the trial level were estimated using the Plackett copula bivariate (R2) model. Criteria for PFS surrogacy required R2 ≥ 0.80 at the trial level. Analysis was performed from January 7 through March 20, 2019.\ud \ud Main Outcomes and Measures: Overall survival and PFS based on measurement of cancer antigen 125 levels confirmed by radiological examination results or by combined GCIG criteria.\ud \ud Results: In this meta-analysis of 17 unique randomized trials of standard (n = 7), intensification (n = 5), and maintenance (n = 5) chemotherapies or targeted treatments with data from 11 029 unique patients (median age, 58 years [range, 18-88 years]), a high correlation was found between PFS and OS at the individual level (τ = 0.724; 95% CI, 0.717-0.732), but a low correlation was found at the trial level (R2 = 0.24; 95% CI, 0-0.59). Subgroup analyses led to similar results. In the external validation, 14 of the 16 hazard ratios for OS in the published reports fell within the 95% prediction interval from PFS.\ud \ud Conclusions and Relevance: This large meta-analysis of individual patient data did not establish PFS as a surrogate end point for OS in first-line treatment of advanced ovarian cancer, but the analysis was limited by the narrow range of treatment effects observed or by poststudy treatment. These results suggest that if PFS is chosen as a primary end point, OS must be measured as a secondary end point.

Published
2020

47. Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants

Author

Arakawa, Ayumu, primary, Ichikawa, Hitoshi, additional, Kubo, Takashi, additional, Motoi, Noriko, additional, Kumamoto, Tadashi, additional, Nakajima, Miho, additional, Yonemori, Kan, additional, Noguchi, Emi, additional, Sunami, Kuniko, additional, Shiraishi, Kouya, additional, Kakishima, Hiroki, additional, Yoshida, Hiroshi, additional, Hishiki, Tomoro, additional, Kawakubo, Naonori, additional, Kuroda, Takafumi, additional, Kiyokawa, Takako, additional, Yamada, Kyosuke, additional, Yanaihara, Nozomu, additional, Takahashi, Kazuaki, additional, Okamoto, Aikou, additional, Hirabayashi, Shinsuke, additional, Hasegawa, Daisuke, additional, Manabe, Atsushi, additional, Ono, Kentaro, additional, Matsuoka, Masaki, additional, Arai, Yasuhito, additional, Togashi, Yosuke, additional, Shibata, Tatsuhiro, additional, Nishikawa, Hiroyoshi, additional, Aoki, Kazunori, additional, Yamamoto, Noboru, additional, Kohno, Takashi, additional, and Ogawa, Chitose, additional

Published
2021
Full Text
View/download PDF

49. Interleukin-6 As An Enhancer of Anti-Angiogenic Therapy for Ovarian Clear Cell Carcinoma.

Author

Seki, Toshiyuki, primary, Yanaihara, Nozomu, additional, Shapiro, Jason, additional, Saito, Misato, additional, Tabata, Junya, additional, Yokomizo, Ryo, additional, Noguchi, Daito, additional, Kuroda, Takafumi, additional, Kawabata, Ayako, additional, Suzuki, Jiro, additional, Takahashi, Kazuaki, additional, Matsuzawa, Haruka, additional, Miyake, Misayo, additional, Takenaka, Masataka, additional, Iida, Yasushi, additional, Yanagida, Satoshi, additional, and Okamoto, Aikou, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results